An executive at Maze Therapeutics exercised and sold 30,000 shares on March 10, 2026, generating gross proceeds of ~$1.51M at a weighted-average price of ~$50.45/share. The executive (Bernstein) retains 267,407 stock options convertible into common stock. This appears to be a routine insider liquidity event and is unlikely to materially move the stock.
An executive at Maze Therapeutics exercised and sold 30,000 shares on March 10, 2026, generating gross proceeds of ~$1.51M at a weighted-average price of ~$50.45/share. The executive (Bernstein) retains 267,407 stock options convertible into common stock. This appears to be a routine insider liquidity event and is unlikely to materially move the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
